stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Free cash flow
BridgeBio Pharma, Inc.'s free cash flow for fiscal 2025 was −$455.5M, compared with −$529.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$369.8M. Over the past ten years it has ranged from −$546.2M (fiscal 2021) to −$41.0M (fiscal 2017); the current reading is higher than 44% of that period. BridgeBio Pharma, Inc. ranks 580th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$455.5M | — |
| FY2024 | −$529.6M | — |
| FY2023 | −$529.0M | — |
| FY2022 | −$425.8M | — |
| FY2021 | −$546.2M | — |
| FY2020 | −$407.2M | — |
| FY2019 | −$256.2M | — |
| FY2018 | −$138.8M | — |
| FY2017 | −$41.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$44.5M | — |
| Jun 2026 | −$71.5M | — |
| Mar 2026 | −$197.3M | — |
| Dec 2025 | −$56.5M | — |
| 30 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $664.5M |
| BMRN BioMarin Pharmaceutical Inc. compare | $557.9M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| TECH Bio-Techne Corp compare | $263.2M |
| KYMR Kymera Therapeutics, Inc. compare | −$288.9M |
| BBIO BridgeBio Pharma, Inc. | −$369.8M |
| SMMT Summit Therapeutics PLC compare | −$459.8M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement